The interim data from an ongoing phase 1 trial of the TIM-3 inhibitor sabatolimab (MBG453) in combination with azacitidine demonstrated CR/CRi in 2 out of 5 patients with TP53m-AML and an ORR of 71% (10 out of 14) in patients with TP53-mutated higher-risk MDS [91]. The gene discussed is TP53; the disease is myelodysplastic syndrome.